Please assess the completion status of the following clinical trial:

Trial Title: Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed the 6-Month Treatment Period in pivotal study M12-671.~* Agrees to use required birth control methods during the study through Month 6 of the Post-treatment Follow-up period~Exclusion Criteria:~* Clinically significant gynecological condition~* Bone mineral density (BMD) loss greater than or equal to 8 percent in the spine, femoral neck or total hip~* Plans to become pregnant in the next 18 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix 150 mg QD (Type: EXPERIMENTAL): Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
- Elagolix 200 mg BID (Type: EXPERIMENTAL): Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).